Agilent Technologies, Inc. ($A) Earnings (Q2 FY22)

 Agilent Technologies, Inc. ($A) Earnings and Opinion:


Agilent Technologies is a company in the Healthcare sector and operates in the Diagnostics & Research industry. The company provides application focused solutions to the life sciences, diagnostics, and applied chemicals markets worldwide. Agilent Technologies was incorporated in 1999 and is currently headquartered in Santa Clara, California. The company made its debut on the stock market in 1999.

Agilent Technologies Earnings Results:

  • Revenues of $1.72B beating expectations of $1.64B
  • Adjusted EPS of $1.34 beating expectations $1.20
  • Guidance all beat consensus estimates except for revenues for Q3
Opinion:
Agilent Technologies is currently moving higher after reporting earnings after the closing bell today. The company came out with a solid quarter and guidance was pretty solid compared to consensus estimates. They were able to kill it on Life Sciences revenues but missed on Diagnostics and CrossLab revenues. The misses were slight, so there isn't too much concern when it comes to that. As far as guidance, the revenue for Q3 was guided lower than estimates but by a slim margin. These are things being overlooked by investors and it makes sense to why the stock is soaring right now. As far as valuation goes, the P/E ratio is 31.37 which is higher than the industry average of 24. The P/S ratio sits at 6.07 and a current ratio of 2.01. The cash sits at around $1.21B and total debt is around $2.91B. This is okay because the stock is still in the growth faze. They have had profitability for a while and currently distribute a dividend. The dividend is small at a 0.63% yield, but it is better than nothing for a company going to achieve growth. In my opinion, this doesn't look too bad of a stock. I personally am not a big fan of the healthcare industry due to all of the fluctuations and pharmaceuticals. However, this company has a solid track record and provides some pretty strong research which makes it less volatile. Looking at the P/E ratio compared to industry averages, it seems as if the stock may be a little overvalued right now. I am going to stay out of this one for now, but it doesn't seem to be a bad play, however it comes with a lot of risk. 

*Information from Zacks, Yahoo Finance, Consensus Guru, and CMLVIZ

Comments

Popular posts from this blog

Weekly Earnings Review: September 25, 2023- September 29, 2023

Weekly Earnings Review: October 16, 2023- October 20, 2023

Weekly Earnings Review: November 27, 2023- December 1, 2023